CTLA4 and Hepatitis: We first evaluated the incidence of hepatitis and other immune-related adverse events (irAE) in a prospectively recruited discovery cohort of n = 39 patients after initiation of anti-PD-1 & anti-CTLA4 therapy due to advanced melanoma over a period of 100 days.